143

Neurology
Focuses on brain health.
Sub Categories on Neurology
Latest Articles
FDA panel reviews 1st new Alzheimer's drug in 2 decades

FDA panel reviews 1st new Alzheimer's drug in 2 decades

by Marilynn Marchione and Matthew PerroneIn this Dec. 12, 2019 photo provided by Biogen, a scientist works on Alzheimer's disease research in a laboratory at the drugmaker's headquarters in Ca

FDA panel reviews 1st new Alzheimer's drug in 2 decades

by Marilynn Marchione and Matthew PerroneIn this Dec. 12, 2019 photo provided by Biogen, a scientist works on Alzheimer's disease research in a laboratory at the drugmaker's headquarters in Ca
Overlapping mechanisms in HIV cognitive disorders and Alzheimer's disease

Overlapping mechanisms in HIV cognitive disorders and Alzheimer's disease

by Society for NeuroscienceAβ oligomers are elevated in the brains of HIV(+) cases. Paraffin-embedded tissue sections from hippocampus of HIV(-) and HIV(+) individuals were prepared for immunoflu

Overlapping mechanisms in HIV cognitive disorders and Alzheimer's disease

by Society for NeuroscienceAβ oligomers are elevated in the brains of HIV(+) cases. Paraffin-embedded tissue sections from hippocampus of HIV(-) and HIV(+) individuals were prepared for immunoflu
GluN3A knockout mouse: Alternative model for Alzheimer's neurodegeneration

GluN3A knockout mouse: Alternative model for Alzheimer's neurodegeneration

by Emory UniversityGluN3A (in the diagram, NR3) is an inhibitory subunit within NMDA receptor assemblies, which function as glutamate-gated cation channels. GluN3A is a key regulator of neuronal

GluN3A knockout mouse: Alternative model for Alzheimer's neurodegeneration

by Emory UniversityGluN3A (in the diagram, NR3) is an inhibitory subunit within NMDA receptor assemblies, which function as glutamate-gated cation channels. GluN3A is a key regulator of neuronal
HBOT showed improvement in Alzheimer's disease

HBOT showed improvement in Alzheimer's disease

by Louisiana State UniversityCredit: Louisiana State UniversityDr. Paul Harch, Clinical Professor and Director of Hyperbaric Medicine at LSU Health New Orleans School of Medicine, and Dr. Edward

HBOT showed improvement in Alzheimer's disease

by Louisiana State UniversityCredit: Louisiana State UniversityDr. Paul Harch, Clinical Professor and Director of Hyperbaric Medicine at LSU Health New Orleans School of Medicine, and Dr. Edward
Clinical trial results for lecanemab are a significant step for Alzheimer's, but not a historic breakthrough

Clinical trial results for lecanemab are a significant step for Alzheimer's, but not a historic breakthrough

by University of New South WalesAmyloid plaques and neurofibrillary tangles occur in the brains of patients with Alzheimer's disease. Credit: Ian JosonPartner companies Eisai and Biogen recen

Clinical trial results for lecanemab are a significant step for Alzheimer's, but not a historic breakthrough

by University of New South WalesAmyloid plaques and neurofibrillary tangles occur in the brains of patients with Alzheimer's disease. Credit: Ian JosonPartner companies Eisai and Biogen recen
Lecanemab: Experimental drug is a ray of hope for Alzheimer's disease

Lecanemab: Experimental drug is a ray of hope for Alzheimer's disease

by Frederic Calon and Étienne Aumont,The ConversationCredit: AI-generated imageOn Nov. 30, Eisai and Biogen announced theresults of their latest phase 3 clinical trial in Alzheimer's d

Lecanemab: Experimental drug is a ray of hope for Alzheimer's disease

by Frederic Calon and Étienne Aumont,The ConversationCredit: AI-generated imageOn Nov. 30, Eisai and Biogen announced theresults of their latest phase 3 clinical trial in Alzheimer's d
Dementia more common in adults with HIV

Dementia more common in adults with HIV

(HealthDay)—People older than 50 years with HIV are more likely to have dementia than people without HIV, according to a study published online Nov. 24 inAIDS.Jennifer O. Lam, from Kaiser Perman

Dementia more common in adults with HIV

(HealthDay)—People older than 50 years with HIV are more likely to have dementia than people without HIV, according to a study published online Nov. 24 inAIDS.Jennifer O. Lam, from Kaiser Perman
FDA defends approval of controversial Alzheimer's drug

FDA defends approval of controversial Alzheimer's drug

by Dennis ThompsonThe U.S. Food and Drug Administration has approved the first new drug to treat Alzheimer's disease in nearly two decades, in a controversial decision that left the agency defendi

FDA defends approval of controversial Alzheimer's drug

by Dennis ThompsonThe U.S. Food and Drug Administration has approved the first new drug to treat Alzheimer's disease in nearly two decades, in a controversial decision that left the agency defendi
First 'gene silencing' drug for Alzheimer's disease shows promise

First 'gene silencing' drug for Alzheimer's disease shows promise

by University College LondonEffect of MAPTRxon CSF concentrations of p-tau protein and tau/Aβ42. a, The mean percentage change from baseline in p-tau over time according to dose group. b, T

First 'gene silencing' drug for Alzheimer's disease shows promise

by University College LondonEffect of MAPTRxon CSF concentrations of p-tau protein and tau/Aβ42. a, The mean percentage change from baseline in p-tau over time according to dose group. b, T
HIV drug shown to help protect against build-up of dementia-related proteins in mouse brains

HIV drug shown to help protect against build-up of dementia-related proteins in mouse brains

by University of CambridgeGraphical Abstract. Credit:Neuron(2023). DOI: 10.1016/j.neuron.2023.04.006Cambridge scientists have shown how the brain's ability to clear out toxic prot

HIV drug shown to help protect against build-up of dementia-related proteins in mouse brains

by University of CambridgeGraphical Abstract. Credit:Neuron(2023). DOI: 10.1016/j.neuron.2023.04.006Cambridge scientists have shown how the brain's ability to clear out toxic prot
How COVID-19 might increase risk of memory loss and cognitive decline

How COVID-19 might increase risk of memory loss and cognitive decline

by Natalie C. Tronson,The ConversationCredit: CC0 Public DomainOf all frightening ways that the SARS-COV-2 virus affects the body, one of the more insidious is the effect of COVID-19 on the brai

How COVID-19 might increase risk of memory loss and cognitive decline

by Natalie C. Tronson,The ConversationCredit: CC0 Public DomainOf all frightening ways that the SARS-COV-2 virus affects the body, one of the more insidious is the effect of COVID-19 on the brai
FDA warns 17 companies about illegal Alzheimer disease products

FDA warns 17 companies about illegal Alzheimer disease products

(HealthDay)—A number of warning/advisory letters have been issued to 17 companies for selling illegal products that claim to prevent, treat, or cure Alzheimer disease and other serious conditions, the

FDA warns 17 companies about illegal Alzheimer disease products

(HealthDay)—A number of warning/advisory letters have been issued to 17 companies for selling illegal products that claim to prevent, treat, or cure Alzheimer disease and other serious conditions, the